

## MEDIA RELEASE

## 智利天主教大学的初步结果显示，科兴新冠病毒疫苗的增强剂量可激活针对奥密克戎变种的细胞免疫。

(莎阿南, 1 日讯) 智利科学家宣布，一项正在进行的研究初步结果表明，科兴新冠病毒疫苗加强针可以激活针对新冠变异株奥密克戎的细胞免疫，在先前接受两针疫苗者作为主要受试者中。

该研究由智利天主教大学 (UC) 进行，由免疫学和免疫治疗研究所主任 Alexis M. Kalergis 博士教授领导。该研究的目的是评估由科兴加强针量激活的免疫力是否能够识别新变种，奥密克戎。

根据 Alexis 博士的说法，接种了加强针量的科兴疫苗的受试者拥有 T 细胞，这些 T 细胞以与原始菌株相似的方式针对奥密克戎变种被激活，表明该疫苗含有与奥密克戎变种共有的抗原。

他补充说，研究结果表明，当 T 淋巴细胞与奥密克戎变种接触时，能够产生具有强效杀病毒能力的佳伽马干扰素。

加州大学智利新冠疫苗科学-临床研究学术和科学主任 Susan Bueno 博士强调说：“对变异的这种部分识别很可能有助于疫苗在人群当中的有效性，尽管这些变异已在国内传播。事实上，人口数据显示疫苗迄今有效于控制病毒的变异。”

同时，智利的研究人员也在准备与天主教大学、智利大学、美国加利福尼亚州拉霍亚免疫学研究所和中国科兴合作研究针对新变体的抗体反应。

新致命的奥密克戎(B.1.1.529)新冠病毒关切变种 (VoC) 是发现于南非，同时也报道在欧洲和亚洲。鉴于突变的数量和报告，它可能会传播得更快，并逃避先前感染或疫苗接种的抗体。

科兴新冠病毒加强注射针最近已获得药物管制局的批准并且目前在选定的私人医疗机构提供，如有疑问，请发送电子邮件至 [askme@pharmaniaga.com](mailto:askme@pharmaniaga.com)。

发马公司是国内领先制药公司也是宝实得控股公司集团的旗下公司，与武装部队基金局一起为本公司的主要股东。

-结束-

FOR IMMEDIATE RELEASE

## MEDIA RELEASE

### **About Pharmaniaga Berhad**

Pharmaniaga is the leading pharmaceutical company of Boustead Holdings Berhad Group of Companies, which together with the Armed Forces Fund Board, are the major shareholders of the Company. Listed on the Main Board of Bursa Malaysia, Pharmaniaga's core businesses are generic pharmaceuticals manufacturing; research and development; marketing and sales; warehousing and distribution of pharmaceutical and medical products; supply, trading and installation of medical and hospital equipment as well as community pharmacy.

With a vision to be the premier Malaysian pharmaceutical company, Pharmaniaga is guided by its philosophy of 'Do It Right Always' and is empowered by its motto of Passion for Patients. Strengthened by nine manufacturing plants, nationwide logistics and distribution in Malaysia and Indonesia as well as products registered in 15 countries, Pharmaniaga Group is positioned to be a regional player in the international pharmaceutical arena.

### **Forward-looking statement**

This release may contain certain forward-looking statements with respect to the financial conditions, results of operations and business of the Group and certain plans and objectives of Pharmaniaga Berhad with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

**Issued for Pharmaniaga Group by Corporate Communications Department, Pharmaniaga Berhad. For media enquiries, please contact Dato' Zuhri Iskandar Kamarzaman, Corporate Services Deputy Director of Pharmaniaga Berhad at 03-3342 999 ext 434 or by email [zuhri@pharmaniaga.com](mailto:zuhri@pharmaniaga.com).**

---

<sup>i</sup> <https://www.emol.com/noticias/Nacional/2021/12/24/1042099/estudio-uc-sinovac-omicron.html>